These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 21094833

  • 1. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA, Lee VS, Wang E, Rinella ME, Levitsky J.
    Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
    [Abstract] [Full Text] [Related]

  • 2. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB.
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [Abstract] [Full Text] [Related]

  • 3. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
    Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D.
    Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395
    [Abstract] [Full Text] [Related]

  • 5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 7. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
    Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, Hou NJ, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML.
    J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
    [Abstract] [Full Text] [Related]

  • 8. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW, O'Brien CB, Cirocco R, Montalbano M, de Medina M, Ruiz P, Khaled AS, Bejarano PA, Safdar K, Hill MA, Tzakis AG, Schiff ER.
    Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 10. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M.
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon.
    Schmidt SC, Bahra M, Bayraktar S, Berg T, Schmeding M, Pratschke J, Neuhaus P, Neumann U.
    Dig Dis Sci; 2010 Jul; 55(7):2063-9. PubMed ID: 19798575
    [Abstract] [Full Text] [Related]

  • 14. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD.
    World J Gastroenterol; 2015 May 28; 21(20):6236-45. PubMed ID: 26034358
    [Abstract] [Full Text] [Related]

  • 15. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V.
    Transplant Proc; 2011 Dec 28; 43(10):3824-8. PubMed ID: 22172854
    [Abstract] [Full Text] [Related]

  • 16. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR.
    Liver Int; 2015 Nov 28; 35(11):2433-41. PubMed ID: 26058570
    [Abstract] [Full Text] [Related]

  • 17. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L, Iacob S, Grigorescu M, Sporea I, Sirli R, Damian D, Gheorghe C, Iacob R.
    J Gastrointestin Liver Dis; 2009 Mar 28; 18(1):51-6. PubMed ID: 19337634
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H, Liu Z, Sun Y, Li H, Zhou S, Zhou X, Gao Y, Tang R, Zhang D, Zhang M.
    Ann Transplant; 2015 May 11; 20():263-8. PubMed ID: 25975740
    [Abstract] [Full Text] [Related]

  • 19. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
    Lerias de Almeida PR, Alves de Mattos A, Valle Tovo C.
    Ann Hepatol; 2010 May 11; 9(2):150-5. PubMed ID: 20526007
    [Abstract] [Full Text] [Related]

  • 20. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
    Kornberg A, Küpper B, Tannapfel A, Thrum K, Bärthel E, Habrecht O, Settmacher U.
    Transplantation; 2008 Aug 15; 86(3):469-73. PubMed ID: 18698252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.